Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emd-1204831. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 0.71 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emd-1204831 SCHEMBL2347708 | 1.00 | MET (0.71) | METNQO2 | |
| Emd-1204831 SCHEMBL2346403 | 0.99 | MET (0.70) | METNQO2 | |
| Emd-1204831 SCHEMBL2350245 | 0.95 | MET (0.75) | METNQO2 | |
| SCHEMBL3088037 | 0.92 | MET (0.69) | METNQO2 | |
| SCHEMBL3102513 | 0.88 | MET (0.64) | METNQO2 | |
| SCHEMBL2456034 | 0.88 | MET (0.69) | METNQO2 | |
| SCHEMBL2460056 | 0.88 | MET (0.71) | METNQO2 | |
| SCHEMBL15164583 | 0.88 | MET (0.63) | METNQO2 | |
| SCHEMBL3083964 | 0.88 | MET (0.63) | METNQO2 | |
| SCHEMBL3091288 | 0.87 | MET (0.70) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586599-B2 | Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2013-11-19 | — | — | US | claimed |
| EP-2361250-B1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-20110257180-A1 | Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-10-20 | — | — | US | claimed |
| EP-2361250-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-08-31 | — | — | EP | claimed |
| WO-2010072295-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | claimed |
| US-8586599-B2 | Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof | MERCK PATENT GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| EP-2361250-B1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20110257180-A1 | Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-10-20 | — | — | US | disclosed |
| EP-2361250-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010072295-A1 | NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257180-A1 | Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof | MAP4K2, MAP3K13, MAP3K12 | MET 833/4885NQO2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.